PortfoliosLab logoPortfoliosLab logo
Guardant Health, Inc. (GH)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US40131M1099
CUSIP
40131M109
IPO Date
Oct 4, 2018

Highlights

Market Cap
$11.88B
Enterprise Value
$13.19B
EPS (TTM)
-$3.30
Total Revenue (TTM)
$982.02M
Gross Profit (TTM)
$633.01M
EBITDA (TTM)
-$375.72M
Year Range
$36.36 - $120.74
Target Price
$124.64
ROA (TTM)
-20.67%
ROE (TTM)
419.18%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Guardant Health, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Guardant Health, Inc. (GH) has returned -9.57% so far this year and 116.83% over the past 12 months.


Guardant Health, Inc.

1D
7.16%
1M
-1.63%
YTD
-9.57%
6M
47.84%
1Y
116.83%
3Y*
57.95%
5Y*
-10.06%
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Oct 4, 2018, GH's average daily return is +0.15%, while the average monthly return is +3.13%. At this rate, your investment would double in approximately 1.9 years.

Historically, 52% of months were positive and 48% were negative. The best month was Feb 2019 with a return of +65.2%, while the worst month was Dec 2022 at -48.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 10 months.

On a daily basis, GH closed higher 49% of trading days. The best single day was Dec 3, 2018 with a return of +28.6%, while the worst single day was Dec 16, 2022 at -27.1%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202611.65%-17.66%-1.63%-9.57%
202553.78%-9.43%0.12%10.87%-14.00%28.11%-21.25%64.52%-7.33%48.88%16.56%-5.79%234.34%
2024-18.93%-13.36%8.58%-12.75%50.56%6.57%21.64%-27.18%-10.32%-4.62%62.75%-14.21%12.94%
202315.55%-1.72%-24.12%-3.75%29.96%22.10%8.99%0.15%-24.16%-12.69%-2.74%7.47%-0.55%
2022-30.46%-4.72%-0.05%-6.85%-33.58%-1.56%24.37%-0.22%7.53%-8.04%5.74%-48.03%-72.81%
202120.65%-5.35%3.72%4.15%-21.93%0.06%-11.59%15.91%-1.78%-6.58%-9.99%-4.85%-22.39%

Benchmark Metrics

Guardant Health, Inc. has an annualized alpha of 21.88%, beta of 1.34, and R² of 0.15 versus S&P 500 Index. Calculated based on daily prices since October 05, 2018.

  • This stock captured 142.42% of S&P 500 Index gains and 122.64% of its losses — amplifying both gains and losses, but participating more in upside than downside.
  • R² of 0.15 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
21.88%
Beta
1.34
0.15
Upside Capture
142.42%
Downside Capture
122.64%

Return for Risk

Risk / Return Rank

GH ranks 89 for risk / return — in the top 89% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.


GH Risk / Return Rank: 8989
Overall Rank
GH Sharpe Ratio Rank: 9191
Sharpe Ratio Rank
GH Sortino Ratio Rank: 9090
Sortino Ratio Rank
GH Omega Ratio Rank: 8787
Omega Ratio Rank
GH Calmar Ratio Rank: 9090
Calmar Ratio Rank
GH Martin Ratio Rank: 8989
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Guardant Health, Inc. (GH) and compare them to a chosen benchmark (S&P 500 Index).


GHBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

2.05

0.90

+1.16

Sortino ratio

Return per unit of downside risk

2.91

1.39

+1.52

Omega ratio

Gain probability vs. loss probability

1.36

1.21

+0.15

Calmar ratio

Return relative to maximum drawdown

3.97

1.40

+2.57

Martin ratio

Return relative to average drawdown

9.89

6.61

+3.28

Explore GH risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Guardant Health, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Guardant Health, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Guardant Health, Inc. was 91.03%, occurring on Apr 19, 2024. The portfolio has not yet recovered.

The current Guardant Health, Inc. drawdown is 48.43%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.03%Feb 16, 2021800Apr 19, 2024
-46.47%Aug 9, 2019151Mar 16, 2020135Sep 25, 2020286
-34.74%Mar 18, 201925Apr 22, 201975Aug 7, 2019100
-29.44%Dec 7, 201812Dec 24, 201835Feb 14, 201947
-19.99%Oct 18, 20188Oct 29, 201824Dec 3, 201832

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Guardant Health, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Guardant Health, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for GH relative to other companies in the Diagnostics & Research industry. Currently, GH has a P/S ratio of 11.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items